palbociclib

Explore academic connections and research related to this keyword

131
Views
7
Total Connections
Search More Keywords

Related Articles & Bibliographies

1
Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: An Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
Dawood, Shaheenah;Chiu, Joanne Wing-Yan;Huang, Chiun-Sheng;Nag, Shona;Sookprasert, Aumkhae;Yap, Yoon...
2020 current medical research and opinion DOI: 10.1080/03007995.202... 213 views
2
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure.
Roncato, Rossana;Peruzzi, Elena;Gerratana, Lorenzo;Posocco, Bianca;Nuzzo, Sofia;Montico, Marcella;Or...
2023 Biomedicine & pharmacotherapy = Biomedecine & phar... DOI: 10.1016/j.biopha.202... 29 views
3
Palbociclib stimulates CD8+ T cell response in triple-negative breast cancer via regulating phosphoglycerate dehydrogenase.
Sun, Yuanyuan; Li, Yaqing; Han, Yunwei; Liu, Chenying; Song, Yuanming; Gao, Guangshen
2025 anti-cancer drugs DOI: 10.1097/CAD.00000000... 14 views
4
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.
S. Kahraman; E. Erul; O. Gumusay; D.C. Guven; Sercan Aksoy; G. Basaran; M. Seyyar; E. Sahin; D. Çabu...
2025 clinical breast cancer DOI: 10.1016/j.clbc.2025.... 31 views

Related Journals

current medical research and opinion
ISSN: 1473-4877 615 views
BMC cancer
ISSN: 1471-2407 664 views
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007 743 views

Related Research Groups

No Research Groups Found

No research groups are currently associated with this keyword.

Explore Related Keywords

Breast cancer cdk4/6 inhibitor practical guidance body mass index treatment adherence her-negative breast cancer hormon receptor-positive progression free survival triple-negative breast cancer immunologic memory efficacy oncology treatment real-world turkish hormone group fulvestrant ribociclib cancer: